Opportunistic infections in patients with HIV and AIDS: Fungal and parasitic infections

Journal Medical Libanais

Volumn 54, Issue 2, 2006, Pages 84-90

  Martinez, Jeffrey ^a   Temesgen, Zelalem ^a,b  

^a Mayo Clinic College of Medicine   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; AMPHOTERICIN B; ANTIRETROVIRUS AGENT; ATOVAQUONE; CLINDAMYCIN; CLOTRIMAZOLE; COTRIMOXAZOLE; DAPSONE; FLUCONAZOLE; FLUCYTOSINE; FOLINIC ACID; ITRACONAZOLE; KETOCONAZOLE; MANNITOL; NITAZOXANIDE; NYSTATIN; PENTAMIDINE; PYRIMETHAMINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BRAIN BIOPSY; CANDIDA; COCCIDIA; COCCIDIOSIS; CRYPTOCOCCUS NEOFORMANS; CRYPTOSPORIDIOSIS; CYCLOSPORA CAYETANENSIS; CYCLOSPORIASIS; ENCEPHALITIS; ESOPHAGUS CANDIDIASIS; FUNGAL MENINGITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; ISOSPORA BELLI; MICROSPORIDA; MICROSPORIDIOSIS; MYCOSIS; OPPORTUNISTIC INFECTION; OROPHARYNX CANDIDIASIS; PARASITOSIS; PNEUMOCYSTIS PNEUMONIA; REVIEW; RISK FACTOR; TOXOPLASMA GONDII; TOXOPLASMOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; HEALTH SERVICES ACCESSIBILITY; HUMANS; MYCOSES; PARASITIC DISEASES; WORLD HEALTH;

EID: 33750052932     PISSN: 00239852     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Kaplan JE, Hanson DL, Navin TR et al. Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis. J Infect Dis 1998; 178 (4): 1126-32.
2. El-Sadr WM, Murphy RL, Yurik TM et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. N Engl J Med 1998; 339 (26): 1889-95.
3. Kovacs JA, Gill VJ, Meshnick S et al. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. Jama 2001; 286 (19): 2450-60.
4. Benson CA, Kaplan JE, Masur H et al. Treating opportunistic infections among HIV-infected adults and adolescents: Recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America, 2004: 1-135.
5. Bava AJ, Cattaneo S, Bellegarde E. Diagnosis of pulmonary pneumocystosis by microscopy on wet mount preparations. Rev Inst Med Trop Sao Paulo 2002; 44 (5): 279-82.
6. Ledergerber B, Mocroft A, Reiss P et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med 2001; 344 (3): 168-74.
7. Hill D, Dubey JP. Toxoplasma gondii: transmission, diagnosis and prevention. Clin Microbiol Infect 2002; 8 (10): 634-40.
8. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet 2004; 363 (9425): 1965-76.
9. Montoya JG. Laboratory diagnosis of Toxoplasma gondii infection and toxoplasmosis. J Infect Dis 2002; 185 (Suppl 1): S73-S82.
10. Fichtenbaum CJ. Candidiasis. In: AIDS Therapy. R. Dolin et al., editors. Churchill Livingstone: Philadelphia, 2003: 531-42.
11. Ruhnke M. Mucosal and systemic fungal infections in patients with AIDS: prophylaxis and treatment. Drugs 2004; 64 (11): 1163-80.
12. Rex JH, Walsh TJ, Sobel JD et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000; 30 (4): 662-78.
13. Bicanic T, Harrison TS. Cryptococcal meningitis. Br Med Bull 2004; 72: 99-118.
14. Powderly WG. Current approach to the acute management of cryptococcal infections. J Infect 2000; 41 (1): 18-22.
15. Aberg JA, Powderly WG. Cryptococcosis. In: AIDS Therapy. R. Dolin et al., editors. Churchill Livingstone: Philadelphia, 2003: 498-510.
16. Saag MS, Graybill RJ, Larsen RA et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000; 30 (4): 710-18.
17. Saag MS, Cloud GA, Graybill JR et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999; 28 (2): 291-6.
18. Chen XM, Keithly JS, Paya CV et al. Cryptosporidiosis. N Engl J Med 2002; 346 (22): 1723-31.
19. Smith HV, Corcoran GD. New drugs and treatment for cryptosporidiosis. Curr Opin Infect Dis 2004; 17 (6): 557-64.
20. Leav BA, Mackay M, Ward HD. Cryptosporidium species: new insights and old challenges. Clin Infect Dis 2003; 36 (7): 903-8.
21. Rossignol JF, Hidalgo H, Feregrino M et al. A double-"blind" placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Trans R Soc Trop Med Hyg 1998; 92 (6): 663-6.
22. Curry A, Smith HV. Emerging pathogens: Isospora, Cyclospora and microsporidia. Parasitology 1998; 117 (Suppl): S143-S159.
23. Lewthwaite P, Gill GV, Hart CA et al. Gastrointestinal parasites in the immunocompromised. Curr Opin Infect Dis 2005; 18 (5): 427-35.
24. Flanigan TP, Wanke CA. Cryptosporidium, Isospora, and Cyclospora Infections. In: AIDS Therapy. R. Dolin et al., editors. Churchill Livingstone: Philadelphia, 2003: 438-44.
25. Weiss LM. Microsporidiosis. In: AIDS Therapy. R. Dolin et al., editors. Churchill Livingstone: Philadelphia, 2003: 445-58.